Lanean...
Pretargeting for imaging and therapy in oncological nuclear medicine
BACKGROUND: Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achieved market approval even though it could be considered the ultimate theranosti...
Gorde:
| Argitaratua izan da: | EJNMMI Radiopharm Chem |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer International Publishing
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5824696/ https://ncbi.nlm.nih.gov/pubmed/29503847 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41181-017-0026-8 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|